An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

NCT05667493 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

1400

Enrollment

INDUSTRY

Sponsor class

Conditions

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Interventions

DRUG: Eplontersen

Sponsor

Ionis Pharmaceuticals, Inc.

Collaborators

[object Object]